Payment overview · 2025
General Payments
$47.34
3 reported records · 3 companies
Healthcare provider profile · identity verified
Jason Laney, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HAZLEHURST, GA · NPI 1760708580
Verified facts
What the public records show
CMS Open Payments records show Jason Laney, M.D. received $47.34 in general payments during 2025 across 3 reported records.
Corcept Therapeutics accounted for 42.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.00 | 42.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.74 | 29.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.60 | 28.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $47.34 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.74 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 781 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 264 | 79 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 256 | 39 |
| Lisinopril | Lisinopril | 243 | 79 |
| Losartan Potassium | Losartan Potassium | 224 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 68 |
| Gabapentin | Gabapentin | 187 | 50 |
| Trazodone Hcl | Trazodone Hcl | 182 | 53 |
| Furosemide | Furosemide | 153 | 49 |
| Carvedilol | Carvedilol | 144 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 42 |
| Metformin Hcl | Metformin Hcl | 138 | 40 |
| Alprazolam | Alprazolam | 123 | 32 |
| Montelukast Sodium | Montelukast Sodium | 116 | 33 |
| Allopurinol | Allopurinol | 115 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 52 |
| Ropinirole Hcl | Ropinirole Hcl | 110 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 28 |
| Alendronate Sodium | Alendronate Sodium | 101 | 30 |
| Ozempic | Semaglutide | 98 | 21 |
| Tramadol Hcl | Tramadol Hcl | 95 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 34 |
| Simvastatin | Simvastatin | 84 | 25 |
| Mounjaro | Tirzepatide | 82 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 76 | 21 |
| Potassium Chloride | Potassium Chloride | 75 | 20 |
| Finasteride | Finasteride | 71 | 15 |
| Glipizide | Glipizide | 70 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | suppressed |
| Famotidine | Famotidine | 67 | 16 |
| Pregabalin | Pregabalin | 66 | 15 |
| Sertraline Hcl | Sertraline Hcl | 66 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 23 |
| Meloxicam | Meloxicam | 59 | 22 |
| Jardiance | Empagliflozin | 58 | 14 |
| Eliquis | Apixaban | 55 | 15 |
| Januvia | Sitagliptin Phosphate | 55 | 12 |
| Omeprazole | Omeprazole | 54 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | suppressed |
| Spironolactone | Spironolactone | 46 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 27 |
| Sucralfate | Sucralfate | 44 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Xarelto | Rivaroxaban | 42 | 13 |
| Prednisone | Prednisone | 41 | 34 |
| Atenolol | Atenolol | 40 | suppressed |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 37 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 34 |
| Testosterone Cypionate | Testosterone Cypionate | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | 11 |
| Azithromycin | Azithromycin | 33 | 27 |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 17 |
| Valsartan | Valsartan | 32 | 15 |
| Fentanyl | Fentanyl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | 13 |
| Temazepam | Temazepam | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 19 | 16 |
| Morphine Sulfate | Morphine Sulfate | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $47.34 · 3 records | Corcept Therapeutics | CREON, Korlym, LINZESS, The Cologuard Plus Collection Kit | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error